Joan Harvey Named to PAVmed Board of Directors

PAVmed Inc. has gained a new board member. The company recently named Joan Harvey, to its Board of Directors and will serve as a member of the governing body’s Audit and Compensation committees.

Harvey has more than two decades of health care experience serving in a variety of leadership roles dedicated to improving whole person health and advocating for patients. She is the president of Care Solutions for Evernorth, Cigna Corporation’s health services business. In this role, Harvey oversees Evernorth’s medical, behavioral, and pharmacy clinical programs to meet the diverse needs of health plans, employers, government organizations—and the people they serve.
 
“Ms. Harvey brings a wealth of health care experience, strong track record in strategic and business development, and deep financial acumen to our board,” said Lishan Aklog M.D., PAVmed’s chairman and CEO. “She shares our passion for applying innovative technologies and care models to improve health outcomes, and her contributions will be invaluable as we drive commercial growth, expand our clinical services—including our network of diagnostic test centers—and partner with payors.”

Prior to joining Evernorth, Harvey served in senior leadership roles at Cigna; Medco Health Solutions Inc.; WellPoint 360 Health, a subsidiary of Anthem Inc.; American Imaging Management; and Oxford Health Plans LLC, a subsidiary of UnitedHealth Group. She is a founding member of the Disease Management Association of America, and author of “Asthma Disease Management in the 21st Century” for the Managed Care Handbook: Best Practices in Medical Management.

Harvey earned an MBA from the American Graduate School of International Management and a bachelor’s degree in international relations from Bates College.
 
“PAVmed’s groundbreaking health technologies combined with their strong clinical and research teams have tremendous potential to propel the health care industry forward,” said Harvey. “Their products have the ability to transform how we prevent, diagnose, and treat some of the most complex and debilitating diseases. I look forward to contributing to PAVmed’s ongoing success and transformation into a leading global medical technology company.” 
 
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc., markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed’s CarpX Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure Esophageal Ablation Device with Caldus Technology, which complements EsoGuard and EsoCheck, the NextFlo Intravenous Infusion Set, the PortIO Implantable Intraosseous Vascular Access Device, novel pediatric ear tubes, mechanical circulatory support technology, and glucose monitoring.